Expression of aspartyl beta-hydroxylase and its clinicopathological significance in hepatocellular carcinoma

Modern Pathology

Volumn 19, Issue 2, 2006, Pages 280-286

  Xian, Zhi Hong ^a   Zhang, Shu Hui ^a   Cong, Wen Ming ^a   Yan, He Xin ^a   Wang, Kui ^a   Wu, Meng Chao ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Aspartyl beta hydroxylase; Hepatocellular carcinoma; Immunohistochemistry; Marker; Real time RT PCR

Indexed keywords

ASPARTYL BETA HYDROXYLASE; ISOENZYME; OXYGENASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CELLULAR DISTRIBUTION; CONTROLLED STUDY; EARLY CANCER; ENZYME ACTIVITY; ENZYME SUBUNIT; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 30944448828     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800530     Document Type: Article

References (30)

1. Wu MC, Shen F. Progress in research of liver surgery in China. World J Gastroenterol 2000;6:773-776.
2. Tang ZY. Treatment of hepatocellular carcinoma. Digestion 1998;59:556-562.
3. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999;19:271-285.
4. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002;31:339-346.
5. Feitelson MA, Sun B, Satiroglu Tufan NL, et al. Genetic mechanisms of hepatocarcinogenesis. Oncogene 2002;21:2593-2604.
6. Taouli B, Losada M, Holland A, et al. Magnetic resonance imaging of hepatocellular carcinoma. Gastroenterology 2004;127:S144-S152.
7. Baron RL, Brancatelli G. Computed tomographic imaging of hepatocellular carcinoma. Gastroenterology 2004;127:S133-S143.
8. Suriawinata A, Xu R. An update on the molecular genetics of hepatocellular carcinoma. Semin Liver Dis 2004;24:77-88.
9. Feitelson MA, Pan J, Lian Z. Early molecular and genetic determinants of primary liver malignancy. Surg Clin North Am 2004;84:339-354.
10. Ince N, de la Monte SM, Wands JR. Overexpression of human aspartyl (asparaginyl) beta-hydroxylase is associated with malignant transformation. Cancer Res 2000;60:1261-1266.
11. Maeda T, Taguchi K, Aishima S, et al. Clinicopathological correlates of aspartyl (asparaginyl) beta-hydroxylase over-expression in cholangiocarcinoma. Cancer Detect Prev 2004;28:313-318.
12. Lavaissiere L, Jia S, Nishiyama M, et al. Overexpression of human aspartyl(asparaginyl)beta-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma. J Clin Invest 1996;98:1313-1323.
13. Hirohashi S, Blum HE, Ishak KG, et al. Tumours of the liver and intrahepatic bile ducts. In: Hamilton SR, Aaltonen LA (eds). Pathology and Genetics. Tumours of the Digestive System. World Health Organisation Classification of Tumours. IARC Press: Lyon, 2000, pp 157-202.
14. Geiss GK, An MC, Bumgarner RE, et al. Global impact of influenza virus on cellular pathways is mediated by both replication-dependent and -independent events. J Virol 2001;75:4321-4331.
15. Mididoddi S, McGuirt JP, Sens MA, et al. Isoform-specific expression of metallothionein mRNA in the developing and adult human kidney. Toxicol Lett 1996;85:17-27.
16. Wong N, Chan KY, Macgregor PF, et al. Transcriptional profiling identifies gene expression changes associated with IFN-alpha tolerance in hepatitis C-related hepatocellular carcinoma cells. Clin Cancer Res 2005;11:1319-1326.
17. Smith MW, Yue ZN, Geiss GK, et al. Identification of novel tumor markers in hepatitis C virus-associated hepatocellular carcinoma. Cancer Res 2003;63:859-864.
18. Cheung ST, Wong SY, Leung KL, et al. Granulin-epithelin precursor overexpression promotes growth and invasion of hepatocellular carcinoma. Clin Cancer Res 2004;10:7629-7636.
19. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
20. Spivack SD, Hurteau GJ, Jain R, et al. Gene-environment interaction signatures by quantitative mRNA profiling in exfoliated buccal mucosal cells. Cancer Res 2004;64:6805-6813.
21. De Preter K, Speleman F, Combaret V, et al. Quantification of MYCN, DDX1, and NAG gene copy number in neuroblastoma using a real-time quantitative PCR assay. Mod Pathol 2002;15:159-166.
22. Miyazawa J, Mitoro A, Kawashiri S, et al. Expression of mesenchyme-specific gene HMGA2 in squamous cell carcinomas of the oral cavity. Cancer Res 2004;64:2024-2029.
23. Lal P, Salazar PA, Hudis CA, et al. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol 2004;121:631-636.
24. Dinchuk JE, Henderson NL, Burn TC, et al. Aspartyl beta-hydroxylase (Asph) and an evolutionarily conserved isoform of Asph missing the catalytic domain share exons with junctin. J Biol Chem 2000;275:39543-39554.
25. Maeda T, Sepe P, Lahousse S, et al. Antisense oligodeoxynucleotides directed against aspartyl (asparaginyl) beta-hydroxylase suppress migration of cholangiocarcinoma cells. J Hepatol 2003;38:615-622.
26. Dinchuk JE, Focht RJ, Kelley JA, et al. Absence of post-translational aspartyl beta-hydroxylation of epidermal growth factor domains in mice leads to developmental defects and an increased incidence of intestinal neoplasia. J Biol Chem 2002;277:12970-12977.
27. Sepe PS, Lahousse SA, Gemelli B, et al. Role of the aspartyl-asparaginyl- beta-hydroxylase gene in neuroblastoma cell motility. Lab Invest 2002;82:881-891.
28. Palumbo KS, Wands JR, Safran H, et al. Human aspartyl (asparaginyl) beta-hydroxylase monoclonal antibodies: potential biomarkers for pancreatic carcinoma. Pancreas 2002;25:39-44.
29. Ho SP, Scully MS, Krauthauser CM, et al. Antisense oligonucleotides selectively regulate aspartyl beta-hydroxylase and its truncated protein isoform in vitro but distribute poorly into A549 tumors in vivo. J Pharmacol Exp Ther 2002;302:795-803.
30. Gores GJ. Cholangiocarcinoma: preventing invasion as anti-cancer strategy. J Hepatol 2003;38:671-673.